In this study, we found that mutations in CCT5 are most common in LUSC (> 10%), followed by Esophageal Adenocarcinoma (EAC), Bladder Urothelial Carcinoma (BLCA), and Lung Adenocarcinoma (LUAD), which cumulatively indicates that CCT5 mutations influence cancer progression in different tissues. This evidence concerns the gene CCT5 and lung adenocarcinoma.